Pilot Evaluation of Bupropion for the Treatment of Hot Flashes

Abstract

Bupropion is commonly used in the treatment of nicotine dependence and depression, and in most people, does not cause sexual dysfunction, weight gain, or sedation. Given its attractive side effect profile, the efficacy of other newer antidepressants against hot flashes and anecdotal observations of resolution of hot flashes in some patients taking bupropion for nicotine dependence, it was decided to explore its clinical activity as a hot flash remedy in a pilot study. Between January 1999 and October 2004, 21 patients (7 men and 14 women) were enrolled in the study. Self-completed daily hot flash diaries were used to document the frequency and severity of hot flashes at baseline (week 1) and during the treatment period (weeks 2 through 5). Participants received bupropion 150 mg every morning for the first 3 days and then 150 mg twice per day for a total of 4 weeks. One woman did not provide any hot flash information and was excluded from the analysis. Five women could not complete the study because of side effects. The study did not show a reduction in hot flash frequency and/or severity significantly higher than what would be expected with a placebo. Even though the sample size was small, these results are consistent with bupropion's mechanism of action (norepinephrine reuptake inhibition without serotonergic effects) and what it is now hypothesized about the pathophysiology of hot flashes (increased noradrenergic activity and decreased serotonergic activity). These data suggest that bupropion should not be further investigated as a remedy for hot flashes.

Does Effective Management of Sleep Disorders Reduce Cancer-Related Fatigue?

“…[63] A final trial of mirtazapine reporting insomnia outcomes in the treatment of hot flushes was identified but, as approximately 40% of the study participants were post-menopausal women with no history of breast cancer, the trial was excluded. [64] …”

Gabapentin for the treatment of menopausal hot flashes

“…13 Also, bupropion, an antidepressant, is no different from placebo in reducing hot flashes. 14 Furthermore, Nelson et al 13 recommend these nonhormonal agents for highly symptomatic women who cannot take estrogen and highlight the need for larger, more rigorous trials using standardized outcomes.…”

Risk factors, pathophysiology, and treatment of hot flashes in cancer

“…120 A non-randomized study of mirtazapine 15 to 30 mg per day showed a 59% reduction in hot flashes in 22 women with a risk or history of breast cancer. 121 Recently, an open-label trial was conducted to assess the efficacy of mirtazapine for reliving vasomotor symptoms in 40 breast cancer patients. 122 Results showed a 56% reduction of hot flash frequency and 62% reduction in hot flash scores as compared to baseline; however only 20 participants (50%) completed the 12-week study.…”